Title: Anti-obesity drugs: a review about their effects and their safety.
Journal: Expert opinion on drug safety 20120501
Title: Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120401
Title: [The pharmacological treatment of obesity: past, present and future].
Journal: Orvosi hetilap 20120311
Title: The effect of tesofensine on appetite sensations.
Journal: Obesity (Silver Spring, Md.) 20120301
Title: Anti-Obesity Drugs: A Review about Their Effects and Safety.
Journal: Diabetes & metabolism journal 20120201
Title: New acetylcholinesterase inhibitors for Alzheimer's disease.
Journal: International journal of Alzheimer's disease 20120101
Title: Pharmacological management of binge eating disorder: current and emerging treatment options.
Journal: Therapeutics and clinical risk management 20120101
Title: Serotonergic anti-obesity agents: past experience and future prospects.
Journal: Drugs 20111203
Title: Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
Journal: CNS neuroscience & therapeutics 20111001
Title: Current and future drug targets in weight management.
Journal: Pharmaceutical research 20110801
Title: Comparative efficiency and safety of pharmacological approaches to the management of obesity.
Journal: Diabetes care 20110501
Title: Assessment of acute and chronic pharmacological effects on energy expenditure and macronutrient oxidation in humans: responses to ephedrine.
Journal: Journal of obesity 20110101
Title: Pharmacotherapies for obesity: past, current, and future therapies.
Journal: Journal of obesity 20110101
Title: Pharmacological treatment of obesity in children and adolescents: present and future.
Journal: Journal of obesity 20110101
Title: Weight gain, obesity, and psychotropic prescribing.
Journal: Journal of obesity 20110101
Title: Present and future: pharmacologic treatment of obesity.
Journal: Journal of obesity 20110101
Title: Usage, risk, and benefit of weight-loss drugs in primary care.
Journal: Journal of obesity 20110101
Title: Management of diabetes across the course of disease: minimizing obesity-associated complications.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20110101
Title: The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
Journal: International journal of obesity (2005) 20101101
Title: New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
Journal: Pharmacology, biochemistry, and behavior 20101101
Title: [Recent progress and novel perspectives on obesity pharmacotherapy].
Journal: Arquivos brasileiros de endocrinologia e metabologia 20100801
Title: Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Journal: Clinical pharmacology and therapeutics 20100701
Title: The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
Journal: European journal of pharmacology 20100625
Title: Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
Journal: The AAPS journal 20100601
Title: Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100601
Title: Effect of centchroman coadministration on the pharmacokinetics of metformin in rats.
Journal: Indian journal of pharmacology 20100601
Title: Pharmacological management of appetite expression in obesity.
Journal: Nature reviews. Endocrinology 20100501
Title: Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
Journal: Clinical pharmacokinetics 20100101
Title: [Drug treatment of obesity--current situation and perspectives].
Journal: Casopis lekaru ceskych 20100101
Title: Tackling obesity: new therapeutic agents for assisted weight loss.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Title: [Is there a future for medical treatment of obesity?].
Journal: Ugeskrift for laeger 20091005
Title: [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
Journal: Ugeskrift for laeger 20091005
Title: Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
Journal: Current opinion in investigational drugs (London, England : 2000) 20091001
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090901
Title: Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13.
Journal: Expert opinion on investigational drugs 20090701
Title: Tesofensine and weight loss.
Journal: Lancet (London, England) 20090227
Title: Tesofensine and weight loss.
Journal: Lancet (London, England) 20090227
Title: Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes.
Journal: PloS one 20090101
Title: A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
Journal: Clinical pharmacokinetics 20090101
Title: Triple reuptake inhibitors: the next generation of antidepressants.
Journal: Current neuropharmacology 20081201
Title: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England) 20081129
Title: Is new hope on the horizon for obesity?
Journal: Lancet (London, England) 20081129
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20081001
Title: Triple reuptake inhibitors: a premise and promise.
Journal: Psychiatry investigation 20080901
Title: Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.
Journal: Obesity (Silver Spring, Md.) 20080601
Title: Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
Journal: Archives of neurology 20080501
Title: Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.
Journal: British journal of pharmacology 20080101
Title: Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.
Journal: British journal of clinical pharmacology 20070701
Title: Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.
Journal: Movement disorders : official journal of the Movement Disorder Society 20070215
Title: Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine.
Journal: European journal of pharmacology 20070126
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070101
Title: Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation.
Journal: Neural plasticity 20070101
